Journal article
Benefits, harms, and cost-effectiveness of potential age extensions to the national bowel cancer screening program in Australia
JB Lew, DJB St John, FA Macrae, JD Emery, HC Ee, MA Jenkins, E He, P Grogan, M Caruana, MJE Greuter, VMH Coupe, K Canfell
Cancer Epidemiology Biomarkers and Prevention | AMER ASSOC CANCER RESEARCH | Published : 2018
Abstract
Background: The Australian National Bowel Cancer Screening Program (NBCSP) is rolling out 2-yearly immunochemical fecal occult blood test screening in people aged 50 to 74 years. This study aimed to evaluate the benefits, harms, and cost-effectiveness of extending the NBCSP to younger and/or older ages. Methods: A comprehensive validated microsimulation model, Policy1-Bowel, was used to simulate the fully rolled-out NBCSP and alternative strategies assuming screening starts at 40 or 45 years and/or ceases at 79 or 84 years given three scenarios: (i) perfect adherence (100%), (ii) high adherence (60%), and (ii) low adherence (40%, as currently achieved). Results: The current NBCSP will reduce..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The study was funded by the Department of Health, Australia. This work was also funded via Australian Government Research Training Program Scholarship (formally known as Australian Postgraduate Awards PhD Scholarship) for J.-B. Lew, Translational Cancer Research Network (TCRN) Top-up scholarship, supported by Cancer Institute NSW for J.-B. Lew, National Health and Medical Research Council (NHMRC) PhD Scholarship for E. He, NHMRC Career Development Fellowship (CDFs APP1007994 and APP1082989) for K. Canfell, and Cancer Council New South Wales. This work was performed to underpin the 2017 review of the Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer, which were auspiced by Cancer Council Australia and the Department of Health, Commonwealth of Australia.